Project Grant R01CA285851

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...

The National Cancer Institute (NCI), through the Cancer Cause and Prevention Research Program (CFDA 93.393), awarded a $2,124,826 Project Grant to President and Fellows of Harvard College (Harvard T.H. Chan School of Public Health) to optimize a mobile messaging intervention for increasing colorectal cancer (CRC) screening rates among patients at community health centers. The project aims to use a two-phase process to first determine optimal messaging strategies for maximizing patient engagement...

This $4,174,595 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research led by Vanderbilt University Medical Center to leverage omics and electronic health records data to study the genetics of colorectal adenomas (precancerous lesions) and explore drug repurposing for colorectal cancer prevention. The key objectives are to conduct genome-wide association studies, methylome-wide association studies, transcriptome-wide...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $670,534 Project Grant to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk stratification. The goal is to create a screening test to identify patients who harbor advanced adenomas and should undergo colonoscopy, with a target of 99.5% negative predictive value, 95% sensitivity, and 80% specificity for advanced adenomas....

This $192,888 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a research project at the University of Virginia (UVA) to investigate the use of normal colon organoids for identifying causal genetic variants associated with colorectal cancer risk. The key objectives of the project are to: 1) test the hypothesis that colorectal cancer GWAS genes are cell type-specific, and 2) determine the role of these genes within colon epithelial...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $690,637 to the Beckman Research Institute of the City of Hope to develop and validate a minimally invasive, highly sensitive, and cost-effective blood-based test for the early detection of pancreatic ductal adenocarcinoma (PDAC). The test will harness the potential of 5-methylcytosine (5MC) and 5-hydroxy methylcytosine (5HMC) DNA modifications on circulating...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...

The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...

The National Cancer Institute (NCI) awarded a $697,198 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of California, San Diego (UC San Diego Health) for the project "Optimal Early Colorectal Cancer Screening Initiation" from January 1, 2025 to December 31, 2027. The grant supports research to develop a targeted colorectal cancer screening strategy for adults aged 45-49, with the goal of maximizing screening uptake and...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $405,973 to Intus Biosciences LLC (DBA Shoreline Biome LLC) to develop and validate a novel non-invasive, high-throughput fecal microbiome-based screening platform for the detection of colorectal cancer (CRC) and advanced adenoma (AA) precancerous lesions. The platform, called TITAN-1, utilizes machine learning to analyze fecal samples collected at home, with the goal of...